Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.

Eur J Neurol · 2022 · PMC9321632 · PMID 35274413

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendp = 0.067so close (0.05 < p ≤ 0.1)

sc IFN β‐1a‐ versus placebo‐treated patients Patients treated with sc IFN β‐1a had a lower mean (±SD) number of new/enlarging lesions ( n = 273; 6.9 ± 10) compared with placebo‐treated patients ( n = 134; 10.9 ± 16, p < 0.01), while the lesion volume increase of new/enlarging lesions showed a trend towards reduction in treated patients (0.47 ± 0.99 vs. 0.88 ± 1.48 cm 3 , p = 0.067), after adjusting for age, sex, center, and conversion.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.